Hepatic absorbed radiation dosimetry during I-131 Metaiodobenzylguanadine (MIBG) therapy for refractory neuroblastoma

Purpose To compare the prediction of therapeutic hepatic radiation-absorbed dose rates from tracer imaging plus a linearity assumption to estimation based on intra-therapy imaging in 131 I metaiodobenzylguanidine (MIBG) therapy of refractory neuroblastoma. Materials and methods Conjugate-view images...

Full description

Saved in:
Bibliographic Details
Published in:European Journal of Nuclear Medicine 2008-11, Vol.35 (11), p.2105-2112
Main Authors: Koral, Kenneth F., Huberty, John P., Frame, Bill, Matthay, Katherine K., Maris, John M., Regan, Denise, Normolle, Daniel, Yanik, Gregory A.
Format: Article
Language:English
Subjects:
Cancer
Cardiology
Imaging
Liver
Medicine
Medicine & Public Health
Nervous system
Nuclear Medicine
Oncology
Original Article
Orthopedics
Radiation therapy
Radiology
Side effects
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To compare the prediction of therapeutic hepatic radiation-absorbed dose rates from tracer imaging plus a linearity assumption to estimation based on intra-therapy imaging in 131 I metaiodobenzylguanidine (MIBG) therapy of refractory neuroblastoma. Materials and methods Conjugate-view images of the liver were obtained before therapy for seven patients at seven times after a tracer infusion of 131 I MIBG and at three times after the therapy infusion. Measured liver activities were converted to dose-rate estimates. Three statistical models of the rates assuming double exponential dependences on time were examined. One of the three models allowed for a multiplicative correction to the therapeutic late-phase dose-rate amplitude. Results from that model: (1) the tracer prediction of the late-phase absorbed-dose-rate amplitude was a factor of 1.75 times the intra-therapy-estimated value, and (2) the difference between tracer prediction of the radiation-absorbed dose and intra-therapy estimation of it was statistically significant, and (3) the liver radiation-absorbed dose did not reach 30 Gy. Conclusions A statistical modeling analysis finds that the radiation-absorbed dose after therapy appears to be lower than that which is predicted from the linear scaling with administered activity of the tracer radiation-absorbed dose. Hepatocyte toxicity is the most likely reason but it is not high enough to produce clinically observable results.
ISSN:1619-7070
0340-6997
1619-7089
DOI:10.1007/s00259-008-0873-3